We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Ver4.6
Verapamil Research
Mostly mechanism / observationalLimited safety
7 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Verapamil studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2018–2026 with a typical study size of 88 participants.
Based on 7 studies · 1 meta-analysis · 3 RCTs · 112 total participants
Confidence
Moderate
By outcome
Type-1 diabetes & beta-cell function
Mostly mechanism / observational7 studies
Heart & blood pressure
Too few graded studies1 study
Active research area
6 studies in the last 5 years · Latest meta-analysis: 2026
20182026
1RCTn=88 · small study2023
In children and adolescents with newly diagnosed type 1 diabetes, verapamil partially preserved stimulated C-peptide secretion at 52 weeks (about 30% higher than placebo).
Once-daily oral verapamil added to insulin for 12 months improved mixed-meal-stimulated C-peptide and reduced insulin requirements and hypoglycemic events in adults with recent-onset type 1 diabetes.
Randomized, double-blind, placebo-controlled phase-2 trial (Ver-A-T1D) of oral verapamil added to insulin for 12 months in adults with recent-onset T1D
Improved mixed-meal-stimulated C-peptide AUC (endogenous beta-cell function) at 3 and 12 months — the prespecified primary endpoint
Lower rise in insulin requirements, fewer hypoglycemic events, on-target glycemic control; well tolerated
In type-2 diabetics, verapamil lowered HbA1c (~0.5%) vs placebo; an associated decrease in TXNIP gene expression was seen but did NOT reach statistical significance.
Malayeri, Zakerkish, Ramesh, Galehdari, Hemmati, Angali · Diabetes therapy : research, treatment and education of diabetes and related disorders (2021)
Randomized, double-blind, placebo-controlled 90-day trial of oral verapamil in T2DM patients on metformin and sitagliptin
Verapamil significantly lowered HbA1c (~0.5%) vs placebo
The associated decrease in TXNIP gene expression (and rise in GLP1R) was NOT statistically significant — consistent with, but not confirming, the proposed mechanism in humans
Verapamil, an approved angina/hypertension drug, shows emerging benefit for pancreatic beta cells by elevating and sustaining C-peptide, largely via TXNIP reduction.
Arefanian, Koti, Sindhu, Ahmad, Al Madhoun, Al-Mulla · Frontiers in pharmacology (2023)
Review tracing verapamil from its established cardiovascular uses (angina, hypertension) to its emerging beta-cell-protective role
Summarizes the FDA-approved, cost-effective, well-characterized safety/efficacy profile in cardiovascular disease
Frames the TXNIP-lowering mechanism and other pathways underlying beta-cell protection
Verapamil is among the emerging disease-modifying approaches in early type 1 diabetes, but remains adjunctive to insulin alongside the broader disease-modifying landscape.
Wagner, Füchtenbusch, Hummel, Miszon, Pfützner · Diabetes research and clinical practice (2026)
Review of early detection and emerging disease-modifying therapies in (adult-onset) type 1 diabetes
Places verapamil within the wider disease-modifying landscape (e.g. immunotherapies like teplizumab)
Contextualizes beta-cell preservation as adjunctive and partial, not curative